athenahealth Inc. (NASDAQ:ATHN) Director Brandon H. Hull sold 2,400 shares of the stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $130.00, for a total transaction of $312,000.00. Following the completion of the sale, the director now directly owns 3,987 shares of the company’s stock, valued at approximately $518,310. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
athenahealth Inc. (NASDAQ:ATHN) opened at 127.30 on Thursday. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of 468.01 and a beta of 1.28. The stock’s 50 day moving average price is $123.62 and its 200-day moving average price is $129.75. athenahealth Inc. has a one year low of $114.59 and a one year high of $170.42.
athenahealth (NASDAQ:ATHN) last posted its quarterly earnings data on Thursday, July 21st. The company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by $0.08. The business earned $261.90 million during the quarter, compared to analyst estimates of $274.07 million. athenahealth had a return on equity of 5.16% and a net margin of 1.06%. On average, equities research analysts anticipate that athenahealth Inc. will post $1.77 earnings per share for the current fiscal year.
ATHN has been the subject of several research analyst reports. Evercore ISI upgraded athenahealth from a “hold” rating to a “buy” rating and set a $152.00 target price for the company in a research note on Monday. Deutsche Bank AG cut athenahealth from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $147.00 in a research note on Friday, July 22nd. Zacks Investment Research cut athenahealth from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Canaccord Genuity reiterated a “hold” rating and set a $142.00 target price on shares of athenahealth in a research note on Wednesday, June 29th. Finally, Leerink Swann reiterated a “hold” rating on shares of athenahealth in a research note on Thursday, June 16th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $149.70.
A number of institutional investors have recently bought and sold shares of the company. Advisor Group Inc. acquired a new position in athenahealth during the second quarter worth approximately $118,000. FineMark National Bank & Trust raised its position in athenahealth by 4.5% in the second quarter. FineMark National Bank & Trust now owns 944 shares of the company’s stock worth $130,000 after buying an additional 41 shares in the last quarter. KBC Group NV acquired a new position in athenahealth during the second quarter worth approximately $135,000. Societe Generale acquired a new position in athenahealth during the second quarter worth approximately $176,000. Finally, SG Americas Securities LLC raised its position in athenahealth by 27.7% in the second quarter. SG Americas Securities LLC now owns 1,277 shares of the company’s stock worth $176,000 after buying an additional 277 shares in the last quarter.
athenahealth Company Profile